ArticleCVIR endovascular2026
Central gland detachment following prostate artery embolization: incidence, risk factors and clinical outcomes.
Article in CVIR endovascular, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCentral gland detachment (CGD) is a potential complication following prostate artery embolisation (PAE). There is limited information regarding its incidence, associated risk factors, and voiding and ejaculatory function after CGD.
methodsSixty-five consecutive patients undergoing PAE in a single institution were included in this retrospective cohort study. Baseline demographics, radiologic, procedural and clinical outcome data were gathered for all patients. CGD was diagnosed following clinical review and confirmed via cystoscopy or MRI as required.
resultsSix out of 65 (9.2%) patients undergoing PAE developed CGD. Mean baseline prostate volume was 150 mL. CGD occurred more frequently among patients with prostate volume > 150 mL than among those with volume ≤ 150 mL (19.2% vs. 2.6%, p = 0.03). Embolisation was performed with particles < 300 μm in 11/65 cases; CGD incidence was numerically higher among patients treated with particles < 300 μm than with particles > 300 μm (27.3 vs. 5.6%, p = 0.056), although this association did not reach statistical significance. 4/6 patients required cystoscopic removal of sloughed tissue. After resolution of the acute CGD episode, mean International Prostate Symptoms Scores (IPSS) and quality of life due to urinary symptoms (QOL) scores improved from 22 to 2.3 and from 5.3 to 0.5 respectively. In those with preserved ejaculatory function at baseline, 3/4 CGD patients developed new retrograde ejaculation.
conclusionCentral gland detachment is an uncommon but clinically significant complication of PAE. Severe prostatomegaly may be associated with CGD, and cases can occur despite use of medium-sized particles (> 300 μm). Long-term voiding outcomes are generally favourable, but new ejaculatory dysfunction can occur.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.